Schimizzi Gregory V, Jin Linda X, Davidson Jesse T, Krasnick Bradley A, Ethun Cecilia G, Pawlik Timothy M, Poultsides George, Tran Thuy, Idrees Kamran, Isom Chelsea A, Weber Sharon M, Salem Ahmed, Hawkins William G, Strasberg Steven M, Doyle Maria B, Chapman William C, Martin Robert C G, Scoggins Charles, Shen Perry, Mogal Harveshp D, Schmidt Carl, Beal Eliza, Hatzaras Ioannis, Shenoy Rivfka, Maithel Shishir K, Fields Ryan C
Department of Surgery and the Alvin J. Siteman Cancer Center, Washington University School of Medicine, St Louis, MO, United States.
Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, GA, United States.
HPB (Oxford). 2018 Apr;20(4):332-339. doi: 10.1016/j.hpb.2017.10.003. Epub 2017 Nov 21.
Surgical resection is the cornerstone of curative-intent therapy for patients with hilar cholangiocarcinoma (HC). The role of vascular resection (VR) in the treatment of HC in western centres is not well defined.
Utilizing data from the U.S. Extrahepatic Biliary Malignancy Consortium, patients were grouped into those who underwent resection for HC based on VR status: no VR, portal vein resection (PVR), or hepatic artery resection (HAR). Perioperative and long-term survival outcomes were analyzed.
Between 1998 and 2015, 201 patients underwent resection for HC, of which 31 (15%) underwent VR: 19 patients (9%) underwent PVR alone and 12 patients (6%) underwent HAR either with (n = 2) or without PVR (n = 10). Patients selected for VR tended to be younger with higher stage disease. Rates of postoperative complications and 30-day mortality were similar when stratified by vascular resection status. On multivariate analysis, receipt of PVR or HAR did not significantly affect OS or RFS.
In a modern, multi-institutional cohort of patients undergoing curative-intent resection for HC, VR appears to be a safe procedure in a highly selected subset, although long-term survival outcomes appear equivalent. VR should be considered only in select patients based on tumor and patient characteristics.
手术切除是肝门部胆管癌(HC)患者根治性治疗的基石。在西方医疗中心,血管切除(VR)在HC治疗中的作用尚不明确。
利用美国肝外胆管恶性肿瘤联盟的数据,根据VR状态将接受HC切除术的患者分为:未进行VR、门静脉切除(PVR)或肝动脉切除(HAR)。分析围手术期和长期生存结果。
1998年至2015年期间,201例患者接受了HC切除术,其中31例(15%)接受了VR:19例(9%)仅接受了PVR,12例(6%)接受了HAR,其中2例同时进行了PVR,10例未进行PVR。选择进行VR的患者往往更年轻,疾病分期更高。按血管切除状态分层时,术后并发症发生率和30天死亡率相似。多因素分析显示,接受PVR或HAR对总生存期(OS)或无复发生存期(RFS)无显著影响。
在一个接受HC根治性切除的现代多机构队列中,VR在经过严格挑选的亚组患者中似乎是一种安全的手术,尽管长期生存结果似乎相当。应仅根据肿瘤和患者特征,在特定患者中考虑VR。